BRIEF-Lonza Group Issues Exclusive License To Antharis Therapeutics To Advance Next-Generation Dual Payload ADCS For Gastrointestinal Cancers

June 15 (Reuters) - Lonza Group AG LONN.S:

  • LONZA GROUP AG - ISSUES EXCLUSIVE LICENSE TO ANTHARIS THERAPEUTICS TO ADVANCE NEXT-GENERATION DUAL PAYLOAD ADCS FOR GASTROINTESTINAL CANCERS

  • LONZA GROUP AG: UNDER TERMS OF AGREEMENT, ANTHARIS WILL SECURE RIGHTS TO LONZA'S DUAL-PAYLOAD ADC TECHNOLOGY PLATFORM

  • LONZA GROUP AG - LONZA WILL BE ELIGIBLE TO RECEIVE UPFRONT, POTENTIAL MILESTONE PAYMENTS AND ROYALTY PAYMENTS ON NET SALES.

Source text: ID:nPn7KlzcSa

Further company coverage: LONN.S


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.